Cost analysis of the american college of chest physicians guidelines for deep vein thrombosis prophylaxis in patients undergoing orthopedic arthroplastic surgery

Pharmacotherapy

Volumn 17, Issue 6, 1997, Pages 1286-1291

  Wade, William E ^a   Spruill, William J ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ARTHROPLASTY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; HOSPITAL COST; HUMAN; LUNG EMBOLISM; REVIEW; TOTAL HIP PROSTHESIS;

ANTICOAGULANTS; ARTHROPLASTY; ARTHROPLASTY, REPLACEMENT, HIP; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; GUIDELINES; HUMANS; POSTOPERATIVE COMPLICATIONS; THROMBOPHLEBITIS;

EID: 0030693717     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Turpie AGC, Levine MN, Hirsh J, et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986;315:925-9.
2. Hoek J, Nurmohamed MT, ten Gate H, et al. Prevention of deep vein thrombosis (DVT) following total hip replacement by a low molecular weight heparinoid (ORG 10172). Thromb Haemost 1989;62(suppl):522-8.
3. Hull RD, Raskob GE, Gent M, et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA 1990;263:2313-17.
4. Lassen MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties: comparison of LMW heparin and placebo. Acta Orthop Scand 1991;62:33-8.
5. Cohen SH, Erblich GE, Kauffman MS, et al. Thrombophlebitis following knee surgery. J Bone Joint Surg 1973;55A:106-12.
6. Stulberg BN, Insall JN, Williams GW, et al. Deep-vein thrombosis following total knee replacement: an analysis of 638 arthroplasties. J Bone Joint Surg 1984;66A:194-201.
7. Lynch AF, Bourne RB, Rorabeck CH, et al. Deep vein thrombosis and continuous passive motion after total knee arthroplasty. J Bone Joint Surg 1988;70A:11-14.
8. Stringer MD, Steadman CA, Hedges AR, et al. Deep vein thrombosis after elective knee surgery. J Bone Joint Surg 1989;71B:492-7.
9. Erikkson BI, Kalebo P, Anthmyr BA, et al. Prevention of deep vein thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg 1991;73A:484-93.
10. Mohr DN, Silverstein MD, Ilstrup DM, et al. Venous thromboembolism with hip and knee arthroplasty: current prophylactic practices and outcomes. Mayo Clin Proc 1992;67:855-92.
11. Coventry MB, Nolan DR, Beckenbaugh RD, et al. Delayed prophylactic anticoagulation: a study of results and complications in 2,012 total hip arthroplasties. J Bone Joint Surg 1973;55:1487-92.
12. Haake DA, Berkman SA. Venous thromboembolic disease after hip surgery. Clin Orthop 1989;242:212-18.
13. Clagett CP, Anderson FA, Heit J, et al. Prevention of venous thromboembolism. Chest 1995;108(suppl):312S-29.
14. Ishak M, Morley KD. Deep venous thrombosis after total hip arthroplasty: a prospective study to determine the prophylactic effect of graded pressure stockings. Br J Surg 1981;68:429-32.
15. Barnes RW, Brand RA, Clarke W, et al. Efficacy of graded compression antiembolism stockings in patients undergoing total hip arthroplasty. Clin Orthop 1978; 132:61-77.
16. Gallus A, Raman K, Darby T. Venous thrombosis after elective hip replacement: the influence of preventive intermittent calf compression and of surgical technique. Br J Surg 1983;70:17-19.
17. Paiement GD, Wessubger SJ, Waltman AC. Low-dose warfarin versus external pneumatic compression for prophylaxis against venous thromboembolism following total hip replacement. J Arthroplasty 1987; 2:23-6.
18. Francis CW, Pellegrini VD, Marder VJ, et al. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA 1992;267:2911-15.
19. Haas SB, Insall JN, Scuderi GR, et al. Pneumatic sequential-compression boots compared to aspirin prophylaxis of deepvein thrombosis after total knee arthroplasty. J Bone Joint Surg 1990;72A:27-31.
20. Lynch JA, Baker PL, Polly RE, et al. Mechanical measures in the prophylaxis of postoperative thromboembolism in total knee arthroplasty. Clin Orthop 1990;260:24-9.
21. Hull RC, Raskob GE, Pineo GF, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-6.
22. RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg 1994;76A:1174-85.
23. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty: a randomized double-blind trial, comparing low molecular weight heparin fragment (enoxaparin) to warfarin [abstr]. Blood 1994;84(suppl):246A.
24. Spiro TE, Fitzgerald RH, Trowbridge AA, et al. Enoxaparin, a low molecular weight heparin and warfarin for the prevention of venous thromboembolic disease after elective knee replacement surgery [abstr]. Blood 1994;84(suppl):246A.
25. Heit J, Berkowitz S, Bona R, et al. Efficacy and safety of ardeparin (a LMWH) compared to warfarin for prevention of venous thromboembolism following total knee replacement: a double-blind, dose-ranging study [abstr]. Thromb Haemost 1995;73:978.
26. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of deep vein thromboembolism after major knee surgery: a randomized, double-blind trial, comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992;67:417-23.
27. Spiro TE, Colwell CW, Bona RD, et al. A clinical trial comparing the efficacy and safety of enoxaparin a low molecular weight heparin with unfractionated heparin for the prevention of deep venous thrombosis after elective knee replacement surgery [abstr]. Blood 1993;82(suppl):1624A.
28. Hull R, Delmore TJ, Hirsh J, et al. Effectiveness of intermittent pulsatile elastic stockings for the prevention of calf and thigh vein thrombosis in patients undergoing elective knee surgery. Thromb Res 1979;16:37-45.
29. McKenna R, Galante J, Bachmann F, et al. Prevention of venous thromboembolism after total knee replacement by highdose aspirin or intermittent calf and thigh compression. Br Med J 1980;280:514-17.
30. Bungay KM, Sanchez LA. Types of economic and humanistic outcomes assessments. In: Bungay KM, Osterhaus JT, Paladino JA, et al, eds. Pharmacoeconomic and outcomes: applications for patient care module 1. Kansas City, MO: American College of Clinical Pharmacy, 1996:87-123.
31. Barre J, Pfister G, Potron G, et al. Comparison of the efficacy and safety of Kabi 2165 and standard heparin in the prevention of deep vein thrombosis following total hip arthroplasty. J Mal Vase 1987;12:90-5.
32. Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988;60:407-10.
33. Dechavanne M, Ville D, Berruer M, et al. Randomized trial of low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. Haemostasis 1989;1: 5-12.
34. Eriksson BI, Eriksson E, Wadenvik H, et al. Prevention of deep vein thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg 1991;73A:484-9.
35. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery. Ann Intern Med 1991;114:545-51.
36. Leyvraz PF, Bachmann F, Hoek J, et al. Prevention of deep vein thrombosis after hip replacement: randomized comparison between unfractionated heparin and low molecular weight heparin. BMJ 1991;303:543-8.
37. Colwell CW, Jolla LA, Spiro TE, et al. Use of enoxaparin, a low molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. J Bone Joint Surg 1994;76A:3-14.
38. Colwell CW, Spiro TE. Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. Clin Orthop Related Res 1995;319:215-22.
39. Heaton D, Pearce M. Low molecular weight versus unfractionated heparin: a clinical and economic appraisal. PharmacoEconomics 1995;8(2):91-9.
40. Bergqvist B, Lindgren B, Matzsch T. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin. Br J Surg 1996;83:1548-52.
41. Baily JP, Kruger MP, Solano FX, et al. Prospective randomized trial of sequential compression devices vs. low-dose warfarin for deep venous thrombosis prophylaxis in total hip arthroplasty. J Arthroplasty 1991;6:S29-35.
42. Hull RD, Raskob GE, Pineco GF, et al. Low-molecular-weight heparin compared with less-intense warfarin prophylaxis against venous thromboembolism following major elective hip surgery [abstr]. Blood 1992;80:318.
43. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. Arch Intern Med 1997;157:298-303.
44. Menzin J, Colditz G, Regan M, et al. Cost-effectiveness of enoxaparin versus low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995;155:757-64.
45. Sarasin FP, Bounameaux H. Antithrombotic strategy after total hip replacement. A cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis. Arch Intern Med 1996;156:1661-8.
46. Mol WEM, Egberts TCG. Prophylaxis for venous thromboembolism in hip fracture surgery: total costs and cost-effectiveness in The Netherlands. PharmacoEconomics 1994;5(1):48-55.
47. O'Brien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. Can Med Assoc J 1994;150(7):1083-90.
48. Bootman JL, Larson LN, McGhan WE, et al. Pharmacoeconomic research and clinical trials: concepts and issues. Drug Intell Clin Pharm 1989;23:693-7.
49. Bootman JL. Pharmacoeconomics and outcomes research. Am J Health-Syst Pharm 1995;53(suppl 3):S16-19.
50. Lee JT, Sanchez LA. Interpretation of "cost-effectiveness" and soundness of economic evaluations in the pharmacy literature. Am J Hosp Pharm 1991;48:2622-7.
51. Lee J, McLaughlin-Miley C, Chatteron ML. Cost-effectiveness analysis. In: Bungay KM, Osterhaus JT, Paladino JA, et al, eds. Pharmacoeconomic and outcomes: applications for patient care module 2. Kansas City, MO: American College of Clinical Pharmacy, 1996:171-93.
52. Anderson DR, O'Brien BJ, Levine MN, et al. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993;119:1105-12.
53. Mamdani MM, Weingarten CM, Stevenson JG. Thromboembolic prophylaxis in moderate-risk patients undergoing elective abdominal surgery: decision and cost-effectiveness analysis. Pharmacotherapy 1996;16(6): 1111-27.
54. Lee J, Battista C. Principles of economic outcomes assessments. In: Bungay KM, Osterhaus JT, Paladino JA, et al, eds. Pharmacoeconomic and outcomes: applications for patient care module 2. Kansas City, MO: American College of Clinical Pharmacy, 1996:7-20.
55. Armstrong EP. Sensitivity analysis. In: Bungay KM, Osterhaus JT, Paladino JA, et al, eds. Pharmacoeconomic and outcomes: Applications for patient care module 2. Kansas City, MO: American College of Clinical Pharmacy, 1996:297-324.
56. Cardinale V, ed. Red book. Montvale NJ: Medical Economics, 1996:199,283,331.